The study published in the Journal of the American College of Nutrition evaluated the herb’s ability to support skin health, by measuring skin perfusion, or the blood flow to the skin, and gene expression.
PrimaVie, a branded shilajit ingredient from Natreon Inc. (New Brunswick, NJ) was recently the focus of a randomized, double-blind, placebo-controlled study published in the Journal of the American College of Nutrition1. The study evaluated the herb’s ability to support skin health, by measuring skin perfusion, or the blood flow to the skin, and gene expression.
In the study, middle aged women took either 125 mg of shilajit, 250 mg of shilajit, or placebo daily for 14 weeks, and were evaluated six times during that period. Results showed that after 14 weeks of supplementation, subjects taking 250 mg of shilajit saw improved skin perfusion when compared to baseline and placebo, and it induced genes relevant to endothelial cell migration, growth of blood vessels, and the extracellular matrix.
“This study adds to the growing clinical evidence for all the anti-aging benefits of PrimaVie shilajit. Along with its earlier clinical studies, it’s proven that PrimaVie shows highly significant upregulations of genes coding collagens (especially, COL1A1) and ECM proteins in skeletal muscle, such effect being synergistic with exercise,” explained Sanni Raju, PhD, CEO of Natreon, in a press release. “It also has shown to improve testosterone levels, mitochondrial function (increased ATP levels), endothelial function, and cardiovascular health in healthy subjects.”
1. A Das et al. “Skin transcriptome of middle-aged women supplemented with natural herbo-mineral shilajit shows induction of microbascular and extracellular matrix mechanisms.” Journal of the American College of Nutrition, Published online ahead of print on June 4, 2019